 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Paul Bunn and David Raben.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.735 |
|
|
|
-
Raben D, Bunn PA. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome? J Clin Oncol. 2012 Nov 10; 30(32):3909-12.
Score: 0.429
-
Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Bar?n AE, Zeng C, Johnson TK, Bunn PA. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):795-805.
Score: 0.251
-
Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004 Aug; 3(8):977-83.
Score: 0.243
-
Raben D, Helfrich B, Bunn PA. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 2004; 59(2 Suppl):27-38.
Score: 0.234
-
Raben D, Helfrich B, Ciardiello F, Bunn PA. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. 2003 Aug; 41 Suppl 1:S15-22.
Score: 0.227
-
Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
Score: 0.205
-
Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007 Jun; 6(6):1683-91.
Score: 0.074
-
Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Bar?n A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 01; 12(23):7117-25.
Score: 0.072
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|